HomeMarket NewsRevolutionary Rezzayo data published in prestigious medical journal

Revolutionary Rezzayo data published in prestigious medical journal

Actionable Trade Ideas

always free

Scientist taking a sample out of a petri dish using a pipette


The stocks of Cidara Therapeutics (NASDAQ:CDTX) soared in early trading on Tuesday, lifted by the exciting announcement by Cidara and its partner Melinta Therapeutics. The companies revealed the release of consolidated data from two advanced clinical trials for the breakthrough antifungal medication Rezzayo in the management of candidemia and invasive candidiasis.

The data was aggregated from a pivotal Phase 3 study that demonstrated Rezzayo’s equivalence to caspofungin in terms of all-cause mortality, along with a Phase 2 study providing further evidence of its efficacy. The pooled data has been showcased in

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.

Related Articles